← Back to Cognitive Deep Dive

Cerebrolysin

Porcine brain-derived peptide mix — neurotrophic factors

Protocol Summary

Route
SubQ (community-reported) / IM
Dose Range
1–5 mL per administration
Cycling
20 days on, 2–3 courses/year
Evidence Tier
RCT

Traditionally IV; subq use is community-reported. Clinical data reflects IV administration.

Primary Benefits

Safety Profile

Well-studied in clinical settings (IV). SubQ data limited to community reports. Injection site reactions, headache, dizziness.

Research Findings

from peptide_kb — updated weekly

human-rct,meta-analysis,animal human-rct,meta-analysis,animal (1)

Cerebrolysin: Neuropeptide Complex — Benefits, Dosage, and Protocol
research_synthesis 2026-04-24 source →
Cerebrolysin is a complex neuropeptide mixture (not a single peptide) derived from enzymatic hydrolysis of porcine brain tissue. Composition: ~75% free L-amino acids + ~25% low-MW neuropeptides (BDNF, NGF, CNTF, GDNF fragments). Crosses BBB due to <10kDa molecular weight. Approved in 44+ countries (EU, Asia) for stroke/AD/TBI — NOT FDA approved. Benefits: neuroprotection, neurogenesis, BDNF upregulation, synaptic regeneration, dendritic density, anti-inflammatory, antioxidant, mitochondrial energy optimization. Clinical evidence: meta-analysis of 9 RCTs for stroke recovery (PMID 29248999); 6 RCTs for Alzheimer's (PMID 21679156, effect size comparable to cholinesterase inhibitors but Cochrane quality rating = very low); 2025 review of 10 TBI studies (1900+ patients). Dosage: 5mL/day (cognitive support/biohacking), 10-20mL/day (neurological recovery). Cycle: 10-20 days on, then off. ROA: IV infusion (20-60 min slow drip) or IM. Pre-made solution — no reconstitution needed. WARNINGS: porcine-derived (contraindicated in pork allergy, anaphylaxis risk), rare seizures in predisposed individuals, severe hypotension with rapid IV infusion.